NTRK1 and amyloidosis: After EGCG treatment, the phosphorylated protein levels of TrkA (P < 0.01, Fig. 11a), c-Raf (P < 0.01, Fig. 11b), ERK1/2 (P < 0.01, Fig. 11c), and CREB (P < 0.01, Fig. 11d) were increased, and the total protein levels were unchanged in the EGCG-treated APP/PS1 group (P > 0.05, Fig. 11a–d), compared with the APP/PS1 group, indicating that EGCG treatment activated the TrkA receptor and its downstream ERK signaling pathway by increasing NGF relative expression, and induced the activation of CREB, an important molecule for amyloidosis, learning, and memory.